Short Interest in Forte Biosciences, Inc. (NASDAQ:FBRX) Drops By 75.6%

Posted by Latisha Jones on Nov 13th, 2024

Forte Biosciences, Inc. (NASDAQ:FBRX – Get Free Report) was the target of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,000 shares, a decline of 75.6% from the October 15th total of 4,100 shares. Based on an average daily trading volume, of 12,400 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Chardan Capital reissued a “buy” rating and issued a $3.00 target price on shares of Forte Biosciences in a research report on Monday, August 19th.

Check Out Our Latest Research Report on Forte Biosciences

Forte Biosciences Price Performance

NASDAQ:FBRX traded down $0.01 during midday trading on Wednesday, hitting $5.67. The company’s stock had a trading volume of 1,701 shares, compared to its average volume of 4,405. Forte Biosciences has a fifty-two week low of $4.11 and a fifty-two week high of $21.25. The firm’s 50 day moving average is $5.60 and its 200-day moving average is $2.21.

Forte Biosciences (NASDAQ:FBRX – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.11). On average, sell-side analysts forecast that Forte Biosciences will post -22.5 EPS for the current year.

Forte Biosciences Company Profile

(Get Free Report)

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.